Cargando…

No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19

BACKGROUND: The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention. The purpose of this study was to determine whether HCQ administration is associated with improved mortality in COVID-19 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sands, Kenneth, Wenzel, Richard, McLean, Laura, Korwek, Kimberly, Roach, Jonathon, Miller, Karla, Poland, Russell E., Burgess, L. Hayley, Jackson, Edmund, Perlin, Jonathan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834474/ https://www.ncbi.nlm.nih.gov/pubmed/33359949 http://dx.doi.org/10.1016/j.ijid.2020.12.060

Ejemplares similares

Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)–related mortality among patients admitted with noncritical illness
por: Sands, Kenneth E., et al.
Publicado: (2020)

Changes in hospitalized coronavirus disease 2019 (COVID-19) patient characteristics and resource use in a system of community hospitals in the United States
por: Sands, Kenneth E., et al.
Publicado: (2020)

Hyperglycaemia increases mortality risk in non‐diabetic patients with COVID‐19 even more than in diabetic patients
por: Morse, Jennifer, et al.
Publicado: (2021)

Universal Protection: Operationalizing Infection Prevention Guidance in the COVID-19 Era
por: Sands, Kenneth, et al.
Publicado: (2021)

COVID-19 testing processes and patient protections for resumption of elective surgery
por: Schlosser, Michael, et al.
Publicado: (2021)

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
por: Goldin, Laurel, et al.
Publicado: (2021)

Health Care–Associated Infections Among Hospitalized Patients With COVID-19, March 2020-March 2022
por: Sands, Kenneth E., et al.
Publicado: (2023)

Treatment and care received by children hospitalized with COVID-19 in a large hospital network in the United States, February 2020 to September 2021
por: Fuller, Candace C., et al.
Publicado: (2023)

171. The Impact of COVID-19 on Healthcare-Associated Infections
por: Baker, Meghan A, et al.
Publicado: (2021)

COVID-19 Vaccination of HCWs in the First Phase of a Large-Scale Mass Vaccination Program within a Healthcare System
por: Korwek, Kimberly, et al.
Publicado: (2021)

Comment to Sands et al. — No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
por: Hoang, Van Thuan
Publicado: (2021)

Hydroxychloroquine in the prevention of COVID-19 mortality
por: Jorge, April
Publicado: (2021)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

Does hydroxychloroquine reduce mortality for COVID-19?
por: GALLUS, Silvano, et al.
Publicado: (2020)

Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19
por: Zhanel, George G., et al.
Publicado: (2021)

Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
por: Albani, Filippo, et al.
Publicado: (2020)

Impact of Risk Adjustment Using Clinical vs Administrative Data on Hospital Sepsis Mortality Comparisons
por: Rhee, Chanu, et al.
Publicado: (2020)

Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates
por: Misra, Durga Prasanna, et al.
Publicado: (2020)

Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
por: Patel, Tejas K., et al.
Publicado: (2020)

Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
por: Patel, Tejas K., et al.
Publicado: (2020)

891. Epidemiology and Outcomes of Sepsis in Previously Healthy Patients
por: Alrawashdeh, Mohammad, et al.
Publicado: (2019)

Using inpatient electronic medical records to study influenza for pandemic preparedness
por: Fuller, Candace C., et al.
Publicado: (2021)

The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
por: Ayerbe, Luis, et al.
Publicado: (2020)

2476. Universal detection of healthcare-related bacterial transmissions using de novo assembly with short-read whole genome sequencing
por: Pak, Theodore R, et al.
Publicado: (2023)

Risk Adjustment for Sepsis Mortality to Facilitate Hospital Comparisons Using Centers for Disease Control and Prevention’s Adult Sepsis Event Criteria and Routine Electronic Clinical Data
por: Rhee, Chanu, et al.
Publicado: (2019)

Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19
por: Lauriola, Marinella, et al.
Publicado: (2020)

A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19
por: Zervos, Marcus, et al.
Publicado: (2020)

No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”()
por: Pathak, Dr Subodh Kumar, et al.
Publicado: (2020)

The Potential Benefit of Hydroxychloroquine in Chronic Placental Inflammation of Unknown Etiology Associated with Adverse Pregnancy Outcomes
por: Bouariu, Alexandra, et al.
Publicado: (2022)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Hydroxychloroquine shortage
por: Patel, J., et al.
Publicado: (2020)

The benefits and barriers to physical activity and lifestyle interventions for osteoarthritis affecting the adult knee
por: Stevenson, Jonathan Daniel, et al.
Publicado: (2012)

Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients
por: Lacout, Alexis, et al.
Publicado: (2021)

Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
por: Fiolet, Thibault, et al.
Publicado: (2021)

Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients?
por: Ayerbe, Luis, et al.
Publicado: (2021)

4. 137 Hospital Cluster-Randomized Trial of Mupirocin-Chlorhexidine vs Iodophor-Chlorhexidine for Universal Decolonization in Intensive Care Units (ICUs) (Mupirocin Iodophor Swap Out Trial)
por: Huang, Susan S, et al.
Publicado: (2021)

Hydroxychloroquine for COVID-19: Balancing contrasting claims
por: Horby, Peter W., et al.
Publicado: (2020)

Mortality & Hydroxychloroquine; Politics & Pandemic: Strange liaisons lead to strange correlations: Mortalité & Hydroxychloroquine; Politiques & Pandémie: D’étranges liaisons impliquent d’étranges corrélations
por: Elbazidi, H., et al.
Publicado: (2020)

426. COVID-19 Infection Prevention Practices That Exceed CDC Guidance: Balancing Extra Caution Against Impediments to Care
por: Gohil, Shruti K, et al.
Publicado: (2021)

Hydroxychloroquine-induced erythroderma
por: Pai, Sunil B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cqbqjr1p1jfjjvgjqr78719f7a